Use of GLP-1 RAs is associated with a higher risk for ischemic optic neuropathy compared with SGLT2is and DPP4is.

Recent wildfires contribute to a significant reduction in air quality across the Midwestern and Northeastern parts of Canada and the US.

The FDA has granted Fast Track designation to invobenitug, an investigational anti-cDPP3 monoclonal antibody designed to restore RAAS balance in cardiogenic shock.

The FDA has approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor, for adult hypercholesterolemia and HeFH.

Challenging patient interactions can be an adverse influence on the emotions and stress level of emergency physicians.

Among populations surveyed, the odds of stroke were lower among foreign-born individuals and the lowest odds of stroke were seen among those who had recently immigrated. HealthDay News — Individuals ...

Discover how genetic profiles and ancestry may influence the underlying neuropathology and diagnostic accuracy of ...

The table below is a review of notable updates that occurred in June 2026 for investigational products in development (not an inclusive list). Click on the status to view our full coverage. BM-3103 ...

Higher levels of daytime light exposure are associated with a lower risk for dementia, while no association was seen for nighttime light.

The FDA has accepted Apnimed’s NDA for AD109 (aroxybutynin/atomoxetine), a potential first-in-class oral therapy for adults with obstructive sleep apnea.

Counties across the US with limited access to radiation oncology practice sites tend to be rural and have higher levels of poverty.

The FDA has approved Leqembi Iqlik (lecanemab-irmb) subcutaneous weekly starting dose, enabling fully at-home treatment initiation for early Alzheimer disease.